Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes

Author： Medina Miguel Avila Jesús

Publisher： Informa Healthcare

ISSN： 1473-7175

Source： Expert Review of Neurotherapeutics, Vol.13, Iss.5, 2013-05, pp. : 495-503

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK3 Inhibitors and Disease

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 9, 2009-08 ,pp. : 1024-1029

Bentham Science Publishers

Access to resources Recommend Favorite

GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease

By Kypta Robert M

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 10, 2005-10 ,pp. : 1315-1331

Informa Healthcare

Access to resources Recommend Favorite

Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review

Current Topics in Medicinal Chemistry, Vol. 17, Iss. 31, 2018-02 ,pp. : 3361-3369

Bentham Science Publishers

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite

GSK-3 and the neurodevelopmental hypothesis of schizophrenia

By Kozlovsky N. Belmaker R.H. Agam G.

European Neuropsychopharmacology, Vol. 12, Iss. 1, 2002-02 ,pp. : 13-25

Elsevier

Access to resources Recommend Favorite